Pipeline / Targeted Indication / Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Pre-filled system for subcutaneous administration of Remodulin® (treprostinil).

Implantable System for intravenous delivery of Remodulin® (treprostinil).

*FDA requires that certain conditions of Medtronic’s PMA approval of the Implantable System for Remodulin must be satisfied prior to launch or sale of the Implantable System for Remodulin; accordingly, Implantable System for Remodulin labeling may be revised in the process of satisfying such conditions of approval.

Dry Powder Inhaled (DPI) treprostinil in a small handheld device for the treatments of pulmonary arterial hypertension (PAH), and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Prefilled, pre-programmed, single-use PatchPump® for subcutaneous administration of treprostinil.

Next-generation ambulatory micro-infusion pumps with smartphone compatibility.

Oral prodrug being developed to provide increased tolerability and convenience through a once-daily dosing regimen.

Prodrug of treprostinil that is being developed to reduce site pain associated with subcutaneous delivery of treprostinil.

An IP receptor agonist that is a next-generation, once-a-day oral therapy that targets the prostacyclin pathway for patients with pulmonary arterial hypertension (PAH).

Registration phase study in Canada to establish the efficacy and safety of repeat dosing of autologous endothelial progenitor cells (EPCs) transfected with human endothelial nitric oxide synthase (eNOS) and expanded ex-vivo in patients with PAH on top of conventional treatments.

Enhanced Mesenchymal stem cells for the treatment of sepsis and pulmonary arterial hypertension (PAH).